The first study examined the potential of a DC-based vaccine in a murine renal cell carcinoma model and demonstrated high fgl2 expression in tumors that were not responsive to the vaccine.84 A second report investigated the role of FGL2 in glioblastoma multiforme (GBM), a highly aggressive type of brain cancer.85 Using human samples of GBM and low-grade gliomas, they demonstrated that GBM tumors have higher fgl2 gene copy numbers than low-grade gliomas and that higher expression of the fgl2 gene was associated with worse prognosis. The gene discussed is FGL2; the disease is glioma.